Posted by Michael Wonder on 04 Apr 2023
Chiesi Global Rare Diseases announces approval of Ferriprox MR deferiprone extended release tablets in Canada
31 March 2023 - New formulation allows twice-daily dosing in patients with transfusional iron overload due to thalassaemia syndromes when current chelation therapy is inadequate, or sickle cell disease or other anaemias.
Chiesi Global Rare Diseases today announced that Health Canada has approved Ferriprox MR deferiprone extended release tablets 1,000 mg for the treatment of patients with transfusional iron overload due to thalassaemia syndromes when current chelation therapy is inadequate, or sickle cell disease or other anaemias.
